Study identifier:BY9010/M1-409
ClinicalTrials.gov identifier:NCT00163488
EudraCT identifier:N/A
CTIS identifier:N/A
Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray when Administered Concomitantly with Orally Inhaled Fluticasone Propionate/Salmeterol (FP/SAL) in Patients (18-60 Years) with Perennial Allergic Rhinitis (PAR)
Perennial Allergic Rhinitis
Phase 3
No
Ciclesonide
All
106
Interventional
18 Years - 60 Years
Allocation: Randomized
Endpoint Classification: None
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Oct 2016 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|